Skip to main content

Vor Biopharma, Inc. (VOR)

NASDAQ: VOR · IEX Real-Time Price · USD
16.68 0.82 (5.17%)
Oct 22, 2021 4:00 PM EDT - Market closed
Market Cap619.57M
Revenue (ttm)n/a
Net Income (ttm)n/a
Shares Out36.84M
EPS (ttm)-4.36
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume102,008
Open15.94
Previous Close15.86
Day's Range15.40 - 16.80
52-Week Range11.78 - 63.62
Betan/a
AnalystsBuy
Price Target44.80 (+168.6%)
Est. Earnings DateNov 8, 2021

About VOR

Vor Biopharma, Inc., early-stage cell therapy company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

IndustryBiotechnology
IPO DateFeb 5, 2021
Employees109
Stock ExchangeNASDAQ
Ticker SymbolVOR
Full Company Profile

Financial Performance

Financial Statements

Analyst Forecast

According to 4 analysts, the average rating for Vor Biopharma stock is "Buy." The 12-month stock price forecast is 44.80, which is an increase of 168.59% from the latest price.

Price Target
$44.80
(168.59% upside)
Analyst Consensus: Buy

News

Vor to Present Data from its Novel Cell and Genome Engineering Platform at ESGCT

Data covering preclinical proof of concept, manufacturing scale-up, and an in-depth genomic survey of VOR33 for potential off-target editing to be presented at the European Society of Gene and Cell Ther...

4 days ago - GlobeNewsWire

Vor Strengthens Leadership Team with Addition of Dr. Veit Schmelmer as SVP of Program and Alliance Management

CAMBRIDGE, Mass., Oct. 12, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Veit Schmelmer, Ph.D., as Vor's ...

1 week ago - GlobeNewsWire

PureTech Founded Entity Vor Biopharma Announces VOR33 Granted U.S. FDA Fast Track Designation for Acute Myeloid Leukemia

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vor Biopharma announced that the U.S. Food and Drug Administration has granted Fast Track designation to VOR33.

Other symbols:PRTC
1 month ago - Business Wire

Vor Biopharma's Lead Hematopoietic Stem Cell Candidate Fast Tracked In US

The FDA has granted Fast Track designation to Vor Biopharma's (NASDAQ: VOR) VOR33, lead engineered hematopoietic stem cell (eHSC) therapeutic candidate for acute myeloid leukemia (AML). VOR33 consists o...

1 month ago - Benzinga

Vor to Participate in Three Upcoming Investor Conferences

CAMBRIDGE, Mass., Sept. 02, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell and genome engineering company, today announced that the Company will be participating in three up...

1 month ago - GlobeNewsWire

Vor Reports Second Quarter 2021 Financial Results and Provides Company Update

CAMBRIDGE, Mass., Aug. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell and genome engineering company, today reported financial results for the three-month period ended J...

2 months ago - GlobeNewsWire

PureTech Founded Entity Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem C...

BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Vor Announces Collaboration with Janssen to Develop eHSC Transplants Combined with a Bi-Specific Antibody Therapy for AML

Other symbols:PRTC
3 months ago - Business Wire

Vor Biopharma, Janssen Team Up To Develop Combination Therapies For Acute Myeloid Leukemia

Vor Biopharma Inc (NASDAQ: VOR) has collaborated with Janssen Biotech Inc, a unit of Johnson & Johnson (NYSE: JNJ). Under the terms of the collaboration, Vor Biopharma will investigate the combination o...

3 months ago - Benzinga

Vor Biopharma Announces Collaboration with Janssen to Develop Engineered Hematopoietic Stem Cell Transplants Combined...

CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with target...

3 months ago - GlobeNewsWire

Vor Biopharma Names Matthew R. Patterson as Chairman and Promotes Tania Philipp

CAMBRIDGE, Mass., June 11, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies to be used in combin...

4 months ago - GlobeNewsWire

Vor Biopharma to Present at Jefferies and Goldman Sachs Investor Conferences

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targete...

4 months ago - GlobeNewsWire

Vor Reports First Quarter 2021 Financial Results and Provides Company Update

Health Canada clears the CTA for VOR33 clinical trial

5 months ago - GlobeNewsWire

Vor Reports Fiscal Year 2020 Financial Results

IND accepted for VOR33, Vor's lead eHSC product candidate for treatment of AML

6 months ago - GlobeNewsWire

Vor Biopharma to Present at the Barclays Global Healthcare Conference

CAMBRIDGE, Mass., March 05, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies f...

7 months ago - GlobeNewsWire

Vor Biopharma Announces Participation at Cowen 41st Annual Health Care Conference

CAMBRIDGE, Mass., March 01, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies f...

7 months ago - GlobeNewsWire

Vor Biopharma Closes Over $200M Initial Public Offering, Including Full Exercise of Option to Purchase Additional Shares

CAMBRIDGE, Mass., Feb. 09, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies fo...

8 months ago - GlobeNewsWire

Vor Biopharma Announces Pricing of Initial Public Offering Nasdaq:VOR

Vor Biopharma (Nasdaq: VOR), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the prici...

8 months ago - GlobeNewswire

Cell therapy biotech Vor Biopharma files for a $150 million IPO

Vor Biopharma, a Phase 1/2 biotech developing cell therapies for hematological diseases, filed on Friday with the SEC to raise up to $150 million in an initial public offering.

9 months ago - NASDAQ

Vor Biopharma IPO Registration Document (S-1)

Vor Biopharma, Inc. has filed to go public with an IPO on the NASDAQ.

9 months ago - SEC

FDA clears IND application for stem cell therapy to treat AML

The FDA cleared an investigational new drug application for VOR33, an engineered stem cell therapy for the treatment of patients with acute myeloid leukemia who are at high risk for relapse, according t...

9 months ago - Healio